Sun Pharmaceutical Industries Ltd.

Sun Pharma Advanced Research Company (SPARC) and its parent Sun Pharma have entered into a licensing pact for its Elepsia tablets, used in the treatment of epilepsy, in the US market for an upfront payment of $10 million.

As per the agreement, SPARC will license Elepsia XR (Levetiracetam Extended Release tablets) to a wholly-owned subsidiary of Sun Pharma for the US market.

It is also eligible for certain additional milestone payments and defined royalties linked to any future sales of Elepsia XR. Elepsia XR was approved by the USFDA in March 2015.

Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices.